Literature DB >> 30487149

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.

Fabrizio Cantini1, Maurizio Benucci2.   

Abstract

Keywords:  DMARDs (biologic); anti-TNF; psoriatic arthritis; rheumatoid arthritis; spondyloarthritis

Year:  2018        PMID： 30487149     DOI： 10.1136/annrheumdis-2018-214757

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  3 in total

1.  Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis.

Authors:  Bente Glintborg; Rikke Ibsen; Rebecca Elisabeth Qwist Bilbo; Merete Lund Hetland; Jakob Kjellberg
Journal:  RMD Open       Date:  2019-08-12

Review 2.  Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?

Authors:  Roy Fleischmann; Vipul Jairath; Eduardo Mysler; Dave Nicholls; Paul Declerck
Journal:  Rheumatol Ther       Date:  2020-01-16

3.  Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.

Authors:  Maria Chiara Ditto; Simone Parisi; Marta Priora; Silvia Sanna; Clara Lisa Peroni; Angela Laganà; Antonio D'Avolio; Enrico Fusaro
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.